Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PX and Nab-Paclitaxel in Peritoneal Metastatic Mucinous Adenocarcinoma
NCT07454031Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in mucinous adenocarcinoma (MAC), sponsored by Peking University. Primary endpoints: Adverse Events at 21 days and Maximum Tolerated Dose at 21 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
mucinous adenocarcinoma (MAC)
Beyond the preview
Go deeper on NCT07454031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454031.